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Abstract
Introduction: Changes in combination antiretroviral therapy (cART) throughout childhood challenge the continuity of paediatric
HIV treatment. This study aimed to evaluate the prevalence of treatment interruption (TI), including lamivudine (3TC)
monotherapy, and the relationship of TI to virologic and immunologic parameters in HIV-infected paediatric patients.
Methods: Nested within a prospective observational study of a city-wide cohort of HIV-infected persons in the District of
Columbia, this sub-study collected retrospective data on antiretroviral therapy, enrolment (endpoint) and historic (lifelong) CD4
counts and HIV RNA viral load (VL) of the paediatric cohort. TI was defined as interruption of cART ]4 consecutive weeks. Data
on TI, including 3TC monotherapy TI (MTI), were collected. Descriptive statistics and univariate testing were used to compare
children with TI and MTI to children on continuous treatment (CT).
Results: Thirty-eight (28%) out of 136 enrolled children (median age12.9 years) experienced TI, with 14 (37%) of those placed
on 3TC MTI. Significantly lower endpoint median CD4 counts (598 cells/mm3 vs. 815 cells/mm3; p0.003) and CD4% (27.5% vs.
33%; p0.006) were observed in the TI cohort as compared to the CT cohort. The median endpoint VL in the overall TI cohort
was 4 times higher than among the CT cohort (1427 copies/mL vs. 5581 copies/mL; pB0.0001). After a median TI duration of
one year, a majority (n31; 82%) of patients with TI restarted cART, including 100% of those with total TI and 53% of those on
MTI, respectively.
Conclusions: In our study, we observed high frequency of the TI in HIV in paediatric HIV clinical practice. All TIs, including 3TC
MTI, were associated with significantly lower endpoint median CD4 counts and higher median VLs, as compared to CT in
paediatric patients. The high frequency of TI and associated poor outcomes suggest a need for a better strategy in managing the
course of the paediatric and adolescent cART.
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Introduction
Combination antiretroviral therapy (cART) has dramatically
improved the outcome of paediatric HIV infection. Supported
by the evidence from the START trial, the 2015 World Health
Organization HIV treatment guidelines recommend a uni-
versal start of cART in all HIV-infected individuals including
children and adolescents [1,2]. The USA and European guide-
lines support universal paediatric cART in infants and young
children and recommend strong consideration for cART at
older age [3,4].
With changes in the child’s age and maturity, paediatric
cART evolves from the administering liquid and powdered/
granulated antiretroviral drugs (ARVs) to swallowing fixed-
dose combinations tablets. This transition requires frequent
adjustment of ARV dosing based on the child’s age and
weight and close monitoring for cART tolerability and toxicity.
Adherence barriers also continue to evolve from acceptability
of paediatric ARVs in infancy to increased peer pressure and
disclosure challenges during puberty [57]. Moreover, in the
areas of highest paediatric HIV epidemic (e.g. sub-Saharan
Africa), continuity of paediatric cART is frequently challenged
by comorbidities, limited availability of paediatric ARVs and
suboptimal paediatric HIV healthcare capacity [810].
Together, these challenges create multiple settings for treat-
ment interruptions (TI) of cART from infancy into adolescence.
Paediatric and adolescent HIV providers have considered
structured TI guided by CD4 count and clinical staging of the
disease [1113]. TI alternatives such as monotherapy with
lamivudine (3TC) and lopinavir/ritonavir (LPV/r) have been
also considered in children [1417].
While existing data support the feasibility of structured TI
in children, data on the long-term effects of TI in paediatric
HIV-infected patients are limited [11,12]. In this study,
we evaluated the prevalence and duration of TI, including
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placement on ARV monotherapy, and compared the virologic
and immunologic outcomes between paediatric patients with
TI and those on continuous treatment (CT) from a perinatal
HIV cohort in Washington, DC, USA.
Methods
Data source
This analysis was conducted as part of a larger city-wide
longitudinal cohort study of HIV-infected persons receiving
care in the District of Columbia (DC), which is aimed to
describe clinical outcomes and improve the quality of care for
patients in Washington, DC, USA [18]. The paediatric Special
Immunology Services (SIS) program at the Children’s National
Health System (CNHS) is 1 of 13 sites participating in the DC
cohort. SIS provides care to 200 children and adolescents
with primarily perinatally acquired HIV. The majority of
patients in care are Black (95%) and female (55%).
Eligibility criteria
HIV-infected children and adolescents (aged 024 years)
treated at SIS were eligible to participate. Informed consent
(parents and participants ]18 years of age) and assent
(717 years of age) were required. The study protocol was
approved by the Institutional Review Boards (IRBs) at the
George Washington University (GWU) and CNHS.
Study design
Demographic data (age, race and place of birth) and retro-
spective immunologic (CD4 count and CD4%, lifetime CD4
nadir), virologic (HIV RNA viral load (VL)) and antiretroviral
therapy (age at initiations of ARVs and ARVs prescribed) data
were collected from the medical records (MR) of patients
enrolled into DC cohort during 2011 to 2013. Immunologic
and virologic data collected at the time of enrolment through
2013 were used as endpoints across the overall study cohort.
TI was defined as a period of at least four consecutive
weeks of discontinuation of cART, including placement on
monotherapy TI (MTI), approved/prescribed by a clinical pro-
vider and documented in the MR. Within the TI cohort, the
patients who underwent a TI with no ARVs prescribed were
classified as having total TI (TTI). Patients who interrupted
cART but were instead prescribed a single ARV 3TC or LPV/r
were classified as MTI cohort. A patient with multiple TIs was
analyzed as one unit using the data associated with the
longest TI period. Patients on cART who did not have TI were
classified as the CT cohort. TI data included age at the start
and end of TI, reasons for TI, CD4 count and VL closest to the
time of starting TI and after the restart of cART, maximal CD4
count prior and after TI and time to reaching maximal CD4
count after restarting cART.
Data analysis
Frequency distributions and summary statistics, including
median and interquartile range (IQR), were used to describe
the demographic, clinical and treatment characteristics in
general and between those on CT compared to those with TI.
Comparisons between groups (CT vs. TI and TTI vs. MTI) were
performed using chi-squared and Wilcoxon rank sum tests as
appropriate. Among those in the TTI cohort who restarted
treatment, maximum CD4 count and VL before and after TI
were compared using Wilcoxon sign rank test. Data were
analyzed using SAS 9.3 (Cary, NC).
Results and discussion
Results
From October 2011 through December 2013, 136 patients
were enrolled (Table 1). The majority (97.8%) were perinatally
infected. At enrolment, the median CD4 count and CD4%
within the overall patient cohort were 726 cells/mm3 and 31%,
respectively. Approximately half of the study cohort had
undetectable or very low VLs with 60 (44%) and 15 (9.4%)
patients with HIV RNA VL B48 copies/mL and 48 to B200
copies/mL, respectively (data not shown). Among those with
detectable VL, the median HIV RNA VL at enrolment was 3397
copies/mL.
Thirty-eight (28%) participants experienced at least one TI
since initiating ARVs. There were six patients with more than
one episode of TI lasting at least four weeks. There were no
statistically significant differences in demographic character-
istics between the TI and CT cohorts (Table 1).
The median CD4 count, CD4% and nadir CD4 count were
significantly lower in those who experienced TI as compared
to patients in the CT cohort (p0.003, 0.006 and 0.04,
respectively; Table 1). There was no difference between the
two cohorts in the highest ever CD4 cell count and CD4%
after HIV diagnosis (data not shown). The median VL in the TI
cohort was almost four times higher than that among children
in the CT cohort (1427 vs. 5581 copies/mL; pB0.0001).
Among the 38 participants who experienced TI, the
median duration of the last cART regimen before TI was
3.97 years and the median age at the time of TI was
10.8 years (Table 2).
More than half of the patients with TI (n23; 61%) had
experienced TTI of cART. Among the remaining 15 (36.8%)
children with TI, 14 (93%) patients with known resistance to
3TC were placed on 3TC MTI, and one patient was switched
to LPV/ritonavir MTI (data not shown). In the overall TI
cohort, the median CD4 count prior to TI was 789 cells/mm3
and the median VL was 2362 copies/mL. The most common
reason for TI was non-adherence (29%), followed by viral
resistance with limited options for alternative cART (11%)
and ARV-related toxicity (5%) (Table 2). In 29% of the patients
with TI, the reason for stopping cART was not documented.
Among 38 patients with TI, 31 (82%) restarted cART after a
median TI duration of one year (Table 3).
All patients with TTI restarted cART (n23; 100%), while
only 8 out of 15 patients (53%) on MTI restarted cART. The
highest CD4 count ever reached prior to TI (1509 cells/mm3
(IQR 11371820)) was significantly higher than the maximal
CD4 count ever reached after TI (706 cells/mm3 (IQR 531
1140); p0.0005), most likely due to the increased age. TTI
and MTI groups did not demonstrate any significant differ-
ences in demographic, immunologic or virologic character-
istics (data not shown). The only finding in this sub-analysis
was the shorter time required by patients in the MTI cohort
(two months (IQR 1.43.5)) to reach their highest CD4 count
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after restarting cART as compared to the patients in the TTI
cohort (7.9 months (IQR 4.222).
Discussion
Convincing evidence of the detrimental effect of TI on the
outcome of HIV disease from adult trials has led to the
abandonment of the structured TI as a therapeutic cART
approach [19,20]. The TI data from paediatric clinical trials,
however, have been more complex [11,12,21]. In resource-
limited settings, structured TI of cART has been evaluated
as a feasible strategic approach to address limited coverage
with paediatric cART [2123]. CHER trial results have
demonstrated that immediate initiation of cART with planned
TI resulted in better long-term outcomes compared to the
deferred cART [22,23]. Most recently, structured TI of
efavirenz-based cART, defined as short-cycle therapy, showed
non-inferiority in viral suppression compared to the CT arm in
HIV-infected adolescents and young adults [13]. These data
advocate for the potential consideration of structured TI in
paediatric cART.
The prevalence of TI in our study (28%) was similar to that
reported across the observational studies of unstructured
TI from developed countries reporting TI in up to 40% of
paediatric populations [2428]. Many of these studies
presented data from the early 2000s with limited options
for alternative paediatric cART and higher ARV-associated
toxicity. Our retrospective cohort included patients up to
17 years of age, some with a history of dual and unboosted
cART, which might have resulted in limited choices for
replacement regimens. Similar to findings from adult and
paediatric studies from the USA and Europe, the most
common reason for TI in our study was non-adherence to
cART [24,2629].
Several studies have suggested higher immunologic resi-
lience and rebound following prolonged TI in children due
to the inherent differences in immune system maturation
compared to adults [11,12,21,23]. Despite the apparent toler-
ability of TI, concern for the delayed formation of drug resis-
tance and long-term immunologic effect in children remained
[11]. In a recent analysis of the three-year follow-up of the
ARROW trial, every month of TI was associated with a 2%
(13%, p0.001) decrease in CD4% among children and the
history of any TI was associated with a trend to increased
mortality (hazard ratio: 2.6 (95% CI 0.710.4)) [21]. In the
CHER study, the majority (80%) of children in the TI arm
reached immunologic and clinical criteria requiring restarting
cART after 4.8 years [23]. Consistent with these studies, in
our paediatric cohort, the endpoint immunologic parameters
in the patients with TI were significantly lower as compared
to those on CT.
Table 1. Characteristics of CT and TI cohorts at enrolment after TI (univariate analysis of associations with demographic and
clinical factors)
Overall cohort
(N136)
Continuous treatment (CT)
(N98)
Treatment interruption (TI)
(N38)
P-value
(CT and TI)
Demographic parameters
Age (years) 12.9 (8.317.1)a 12.4 (8.017.1)a 14.6 (10.716.9)a 0.24
Age of ARVs initiation (years)b 0.64 (0.32.8)a 1 (0.33.7)a 0.5 (0.331.5)a 0.14
Gender 0.36
Male 63 (46%) 43 (44%) 20 (53%)
Female 73 (54%) 55 (56%) 18 (47%)
Race 0.43
Black 117 (86%) 81 (83%) 36 (95%)
Hispanic/Latino 5 (4%) 4 (4%) 1 (3%)
Non-Hispanic 9 (7%) 9 (9%) 0 (0%)
White 5 (4%) 4 (4%) 1 (3%)
Other/unknown
Birthplace 0.42
USA 92 (68%) 64 (65%) 28 (74%)
Africa 17 (13%) 15 (15%) 2 (5%)
Otherc 27 (20%) 19 (19%) 8 (21%)
Immunologic and virologic parameters
CD4 count (cells/mm3) 726 (4901143)a 815 (5451240)a 598 (271897)a 0.003*
CD4% 31 (2237)a 33 (2437.2)a 27.5 (1633)a 0.006*
Nadir CD4 count (cells/mm3) 400 (116608)a 429 (134784)a 282 (88505)a 0.04*
HIV RNA VL (copies/mL) 3397 (20224,928)a 1427 (979132)a 5581 (88577,484)a B0.0001*
ARVs, antiretroviral drugs; VL, viral load.
aMedian (IQR); bany initial ARVs, including dual and unboosted ARV regimens in older participants; cother included Kazakhstan, Philippines,
Trinidad, Ukraine and unknown (not recorded in MR). *pB0.05 are given in bold.
Rakhmanina N et al. Journal of the International AIDS Society 2016, 19:20936
http://www.jiasociety.org/index.php/jias/article/view/20936 | http://dx.doi.org/10.7448/IAS.19.1.20936
3
Structured TI has been linked to holding or bridging
regimen using 3TC or emtricitabine (FTC) monotherapy in
the presence of the M184V HIV resistance mutation to reduce
viral fitness and prevent formation of additional resistance
mutations [14,15]. IMPAACT P1094 study compared the
immunologic outcome of continuing failing cART versus
switching to 3TC/FTCMTI in perinatally infected non-adherent
adolescents [14]. Participants (n17) randomized to 3TC MTI
were more likely than those maintained on failing cART
(n16) to sustain a ]30% decline in CD4 count [14]. Recent
observational data from 71 South African children on 3TC MTI
as an alternative to failing cART reported that a majority of
children (67.5%) on 3TC MTI had a 25% decline in CD4
count; however, only 23% were switched to second- or third-
line cART [15]. In our study, all patients in the TTI group were
restarted on cART, whereas less than half (46%) in the 3TC
MTI cohort restarted cART. We did not observe significant
immunologic or virologic differences between those on TTI
and on 3TC MTI, although a shorter time was required by
patients on 3TC holding regimen to reach their highest CD4
count after restarting cART. The single site and small sample
size limits our ability to generalize these findings.
Conclusions
Due to the developmental changes throughout childhood
and adolescence, TI represents an ongoing challenge to
the continuum of paediatric cART. Prolonged TI can have
potentially detrimental effects on the long-term outcomes in
HIV-infected children. In our study, significantly lower median
CD4 count and higher median VL were observed in children
with a history of TI, including patients on 3TC MTI, as
compared to those on continued cART. A sub-group analysis
suggests a trend for a shorter time for 3TC MTI cohort to
reach their highest CD4 count after restarting cART, which
warrants further evaluation. Finally, the high frequency of TIs
reported in our and other paediatric studies suggests a need
for a better strategy in maintaining the continuity of the
paediatric and adolescent cART.
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